- WKN: 840400
- ISIN: DE0008404005
- Land: Deutschland
Nachricht vom 12.10.2021 | 16:58
Allianz SE: Release of a capital market information
/ Announcement pursuant to Art. 5 (1) lit. b) of Regulation (EU) No 596/2014 and Art. 2 (3) of Delegated Regulation (EU) No2016/1052 / Acquisition of own shares
In the period from October 4, 2021 to, and including, October 8, 2021 Allianz SE has purchased a number of 297,186 shares within the framework of its on-going share buy-back program which has been published by the announcement of August 17, 2021 pursuant to art. 5 (1) lit. a) Regulation (EU) no 596/2014 and Art. 2 (1) Delegated Regulation (EU) No 2016/1052.
Shares were purchased as follows:
Date Number of shares Average price (EUR))
04.10.2021 112,500 195.45
The purchase of shares is carried out exclusively on the electronic trading platform of the Frankfurt Stock Exchange (Xetra) by a credit institution that has been commissioned by Allianz SE.
Detailed transaction information pursuant to Art. 2 (3) Delegated Regulation(EU) No 2016/1052 can be found on the website of Allianz SE (www.allianz.com).
Independently from the on-going share buy -back program, Allianz SE has acquired between October 7, 2021 and October 8, 2021 a total of 266,500 Allianz shares in the context of the Employee Share Purchase Plan of Allianz ("ESPP"). These shares will be transferred to employees before the end of 2021. The purchase of Allianz shares for ESPP purposes had been announced on August 17, 2021, pursuant to art. 5 (1) lit. a) Regulation (EU) no 596/2014 and Art. 2 (1) Delegated Regulation (EU) No 2016/1052.
The following number of Allianz shares were purchased for ESPP purposes:
Date Number of share Average price (EUR)
04.10.2021 - n.a.
05.10.2021 - n.a.
06.10.2021 - n.a.
07.10.2021 134,000 198.65
08.10.2021 132,500 198.70
The total number of shares purchased for ESPP purposes since October 7, 2021 through, and including, October 8, 2021 amounts to 266,500.
The purchase of Allianz shares for ESPP purposes is carried out exclusively on the electronic trading platform of the Frankfurt Stock Exchange (Xetra) by a credit institution that has been commissioned by Allianz SE.
|End of News||DGAP News Service|
GBC im Fokus
IGEA Pharma N.V. Realignment to CBD extraction
The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.
Der AKTIONÄR News
01. Dezember 18:02 Bayer investiert in Nachhaltigkeit
01. Dezember 18:37 Shop Apotheke und Zur Rose? Beide haben noch Potenzial
01. Dezember 18:50 Bitcoin: Schlägt jetzt die Stunde der Bullen?
01. Dezember 19:00 Gold: Das klingt nicht gut
01. Dezember 19:48 Die OPEC tagt, TotalEnergies steigt
News im Fokus
Symrise verlängert Vorstandsvertrag von Dr. Heinz-Jürgen Bertram vorzeitig bis 2025
01. Dezember 2021, 15:38
FY 2020/2021 Financial Results
16. Dezember 2021
Original-Research: GBC Insider Focus Index (von GBC AG): GBC Insider Focus Index
01. Dezember 2021